“Nexxen International’s stock has faced downward pressure on analyst price targets following mixed Q4 2025 results and a softer CTV segment, yet the consensus remains bullish with an average target around $11-12, implying significant upside from current levels near $7. Recent adjustments reflect caution on near-term growth but optimism on 2026 guidance, data products momentum, … Read more
“China’s leading foundry SMIC reported a 60.7% year-on-year jump in fourth-quarter attributable profit to $172.85 million, surpassing analyst expectations, while revenue climbed 12.8% to $2.49 billion on higher wafer shipments, improved capacity utilization, and a favorable product mix. The results highlight resilience in the semiconductor sector despite geopolitical pressures, with full-year 2025 performance showing solid … Read more
“Haemonetics reported third-quarter fiscal earnings with revenue of $339 million and adjusted earnings per share of $1.31, surpassing analyst expectations. Key segments showed mixed results, with Plasma up 3.5% and Blood Center down 19.6% due to divestitures. The company raised its full-year guidance, projecting adjusted EPS between $4.90 and $5.00 alongside improved organic growth forecasts.” … Read more
“Altria Group reported an adjusted EPS of $1.45 for Q3 2025, missing the consensus estimate of $1.49, while revenue fell 1.7% year-over-year to $5.25 billion against expectations of $5.31 billion; margins faced ongoing pressure from declining cigarette volumes and higher costs, leading to a 4% initial stock drop, though shares have since rebounded with a … Read more